Plus   Neg

Sodexo Confirms H1 Results

Sodexo S.A. (SDXAY.PK) confirmed First Half Fiscal 2017-2018 Results. At its meeting of April 10, 2018, chaired by Sophie Bellon, the Board of Directors approved the consolidated financial statements for the First Half Fiscal 2017-2018 and Denis Machuel, Chief Executive Officer, presented the performance for First Half Fiscal 2017-2018, which ended February 28, 2018.

The company reported that its net profit for the first-half of fiscal year 2018 increased 6.9% or 13.9%, excluding currency effects, to 372 million euros, benefiting from lower exceptional charges than the previous year and a significant reduction in the tax charge.

Underlying net profit was 397 million euro, down by 13.4% or 7.6% excluding currency effects. Overall this was in line with the trend in underlying operating profit.

First Half Fiscal 2018 Revenues of 10.3 billion euros were down 3.2% on the previous period, including a negative currency impact of -6.2%. Net acquisitions contributed +1.3%, with Centerplate consolidated for the first time as of January. Organic growth in the first half was 1.7% or 1.9% excluding the 53rd week impact in North America. Outside North America, on-site organic growth was 4.4%. Organic growth of On-Site Services was 1.6%

For fiscal 2018, the Group now expects to deliver organic revenue growth of between 1% and 1.5%, excluding the 53rd week impact, and an underlying profit margin of around 5.7%.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT